Joseph M Metzger

US Patent:

20050257279, Nov 17, 2005

Filed:

Jun 27, 2003

Appl. No.:

10/518955

Inventors:

Su Qian - Princeton NJ, US
Leonardus Van der Ploeg - Scotch Plains NJ, US
Howard Chen - Westfield NJ, US
Drew Weingarth - East Brunswick NJ, US
Myrna Trumbauer - Yardley PA, US
Joseph Metzger - Fanwood NJ, US

International Classification:

A01K067/027
C12N005/06

US Classification:

800018000, 435354000

Abstract:

Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding agouti-related protein (AgRP). AgRP deficient transgenic animals have a reduced day time respiratory quotient (RQ), indicating that AgRP is involved in the regulation of energy metabolism, resulting in the reduced usage of fat as an energy source. These AgRP deficient transgenic animals can be used to select for and test potential modulators of AgRP. This data allows for methods of screening for AgRP modulators which regulate energy metabolism and caloric utilization. The disclosure also relates to a NPY/AgRP double knockout mouse which can be used to select for and test potential modulators (e.g., agonists or antagonists) of AgRP and/or NPY.

US Patent:

20120165503, Jun 28, 2012

Filed:

Dec 18, 2009

Appl. No.:

13/202524

Inventors:

Paul E. Carrington - Rahway NJ, US
George Eiermann - Rahway NJ, US
Donald Marsh - Rahway NJ, US
Joseph Metzger - Rahway NJ, US
Alessandro Pocai - Rahway NJ, US
Ranabir Sinha Roy - Rahway NJ, US
Bianchi Bianchi - Pomezia, IT
Paolo Ingallinella - Pomezia, IT
Antonello Pessi - Pomezia, IT
Alessia Santoprete - Pomezia, IT
Elena Capito - Pomezia, IT
Richard Dimarchi - Indianapolis IN, US
Brian Ward - Bloomington IN, US

International Classification:

C07K 14/605

US Classification:

530308

Abstract:

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.

US Patent:

20150307580, Oct 29, 2015

Filed:

Apr 14, 2015

Appl. No.:

14/686760

Inventors:

- Rahway NJ, US
- Roma, IT
- Indianapolis IN, US
Joseph M. METZGER - Rahway NJ, US
Alessandro POCAI - Rahway NJ, US
Ranabir SINHA ROY - Rahway NJ, US
Elisabetta BIANCHI - Pommezia, IT
Paolo INGALLINELLA - Pommezia, IT
Antonello PESSI - Pommezia, IT
Alessia PRETE - Pommezia, IT
Elena CAPITO - Pommezia, IT
Richard DIMARCHI - Indianapolis IN, US
Brian WARD - Bloomington IN, US

International Classification:

C07K 14/605

Abstract:

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.